These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38884678)

  • 1. Virus neutralization assays for human respiratory syncytial virus using airway organoids.
    van Dijk LLA; Rijsbergen LC; Rubio BT; Schmitz KS; Gommers L; Comvalius AD; Havelaar A; van Amerongen G; Schepp R; Lamers MM; GeurtsvanKessel CH; Haagmans BL; van Binnendijk R; de Swart RL; de Vries RD
    Cell Mol Life Sci; 2024 Jun; 81(1):267. PubMed ID: 38884678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the respiratory syncytial virus G-directed neutralizing antibody response in the human airway epithelial cell model.
    Kishko M; Catalan J; Swanson K; DiNapoli J; Wei CJ; Delagrave S; Chivukula S; Zhang L
    Virology; 2020 Nov; 550():21-26. PubMed ID: 32866728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.
    Liang B; Kabatova B; Kabat J; Dorward DW; Liu X; Surman S; Liu X; Moseman AP; Buchholz UJ; Collins PL; Munir S
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving ability of RSV microneutralization assay to detect G-specific and cross-reactive neutralizing antibodies through immortalized cell line selection.
    Boukhvalova MS; Mbaye A; Kovtun S; Yim KC; Konstantinova T; Getachew T; Khurana S; Falsey AR; Blanco JCG
    Vaccine; 2018 Jul; 36(31):4657-4662. PubMed ID: 29960801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.
    Corti D; Bianchi S; Vanzetta F; Minola A; Perez L; Agatic G; Guarino B; Silacci C; Marcandalli J; Marsland BJ; Piralla A; Percivalle E; Sallusto F; Baldanti F; Lanzavecchia A
    Nature; 2013 Sep; 501(7467):439-43. PubMed ID: 23955151
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes.
    Fedechkin SO; George NL; Nuñez Castrejon AM; Dillen JR; Kauvar LM; DuBois RM
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31852779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.
    Palomo C; Mas V; Thom M; Vázquez M; Cano O; Terrón MC; Luque D; Taylor G; Melero JA
    J Virol; 2016 Jun; 90(11):5485-5498. PubMed ID: 27009962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.
    Magro M; Mas V; Chappell K; Vázquez M; Cano O; Luque D; Terrón MC; Melero JA; Palomo C
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3089-94. PubMed ID: 22323598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus.
    Liu C; Day ND; Branigan PJ; Gutshall LL; Sarisky RT; Del Vecchio AM
    Virol J; 2007 Jul; 4():71. PubMed ID: 17623075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased susceptibility of human respiratory syncytial virus to neutralization by anti-fusion protein antibodies on adaptation to replication in cell culture.
    Marsh R; Connor A; Gias E; Toms GL
    J Med Virol; 2007 Jun; 79(6):829-37. PubMed ID: 17457900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting.
    van Remmerden Y; Xu F; van Eldik M; Heldens JG; Huisman W; Widjojoatmodjo MN
    Virol J; 2012 Oct; 9():253. PubMed ID: 23114196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies.
    Jones HG; Ritschel T; Pascual G; Brakenhoff JPJ; Keogh E; Furmanova-Hollenstein P; Lanckacker E; Wadia JS; Gilman MSA; Williamson RA; Roymans D; van 't Wout AB; Langedijk JP; McLellan JS
    PLoS Pathog; 2018 Mar; 14(3):e1006935. PubMed ID: 29509814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein.
    Jaberolansar N; Chappell KJ; Watterson D; Bermingham IM; Toth I; Young PR; Skwarczynski M
    Sci Rep; 2017 Sep; 7(1):11130. PubMed ID: 28894111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein.
    Xun G; Song X; Hu J; Zhang H; Liu L; Zhang Z; Gong R
    J Virol; 2021 Aug; 95(18):e0048521. PubMed ID: 34160257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CX3CR1 Is a Receptor for Human Respiratory Syncytial Virus in Cotton Rats.
    Green G; Johnson SM; Costello H; Brakel K; Harder O; Oomens AG; Peeples ME; Moulton HM; Niewiesk S
    J Virol; 2021 Jul; 95(16):e0001021. PubMed ID: 34037420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and qualification of a fast, high-throughput and robust imaging-based neutralization assay for respiratory syncytial virus.
    Sun D; Hsu A; Bogardus L; Rubinstein LJ; Antonello JM; Gurney KB; Whiteman MC; Dellatore S
    J Immunol Methods; 2021 Jul; 494():113054. PubMed ID: 33845088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody based in vitro potency assay as a predictor of antigenic integrity and in vivo immunogenicity of a Respiratory Syncytial Virus post-fusion F-protein based vaccine.
    Djagbare MD; Yu L; Parupudi A; Sun J; Coughlin ML; Rush BS; Sanyal G
    Vaccine; 2018 Mar; 36(12):1673-1680. PubMed ID: 29456016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.